373 related articles for article (PubMed ID: 33215569)
21. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
22. [A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].
Liu Y; You HY; Yan LZ; Jin S; Shang JJ; Shi XL; Yan S; Yao WQ; Wu DP; Liu W; Fu CC
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):330-335. PubMed ID: 35680633
[No Abstract] [Full Text] [Related]
23. [Clinical presentation and prognosis in patients with light-chain amyloidosis with an ultra-high level of serum free light-chain].
Miao HL; Shen KN; Su W; Zhang L; Cao XX; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):199-204. PubMed ID: 33910304
[No Abstract] [Full Text] [Related]
24. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
[TBL] [Abstract][Full Text] [Related]
25. Risk factors, treatments and outcomes of patients with light chain amyloidosis who relapse after autologous stem cell transplantation.
Zhang Y; Guo J; Chen W; Zhao L; Huang X
Bone Marrow Transplant; 2024 Mar; 59(3):350-358. PubMed ID: 38148411
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
27. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
Chakraborty R; Rosenbaum C; Kaur G; Bhutani D; Radhakrishnan J; Mapara MY; Maurer M; Lentzsch S
Br J Haematol; 2023 Jun; 201(5):913-916. PubMed ID: 36896578
[TBL] [Abstract][Full Text] [Related]
28. Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience.
Riva M; Berno T; Cipriani A; Altinier S; Fedrigo M; Noventa F; Adami F
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e970-e974. PubMed ID: 34489209
[TBL] [Abstract][Full Text] [Related]
29. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
Badar T; D'Souza A; Hari P
F1000Res; 2018; 7():. PubMed ID: 30228867
[TBL] [Abstract][Full Text] [Related]
31. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio.
Muchtar E; Gertz MA; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Hwa YL; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Am J Hematol; 2020 Nov; 95(11):1280-1287. PubMed ID: 32681737
[TBL] [Abstract][Full Text] [Related]
32. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
33. Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
Muchtar E; Magen H; Itchaki G; Cohen A; Rosenfeld R; Shochat T; Kornowski R; Iakobishvili Z; Raanani P
Leuk Res; 2016 Feb; 41():56-61. PubMed ID: 26658109
[TBL] [Abstract][Full Text] [Related]
34. Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy.
Milani P; Basset M; Nuvolone M; Benigna F; Rodigari L; Lavatelli F; Foli A; Merlini G; Palladini G
Blood Cancer J; 2020 Sep; 10(8):90. PubMed ID: 32873771
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Jimenez-Zepeda VH; Duggan P; Neri P; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e79-84. PubMed ID: 27101985
[TBL] [Abstract][Full Text] [Related]
36. Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival.
Oubari S; Hegenbart U; Schoder R; Steinhardt M; Papathanasiou M; Rassaf T; Thimm A; Hagenacker T; Naser E; Duhrsen U; Reinhardt HC; Kortum M; Agis H; Schonland S; Carpinteiro A
Haematologica; 2024 Jan; 109(1):220-230. PubMed ID: 37439344
[TBL] [Abstract][Full Text] [Related]
37. [The diagnostic and prognostic values of serum free light chain in patients with primary light chain amyloidosis].
Zhang CL; Feng J; Shen KN; Su W; Zhang CL; Huang XF; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):942-945. PubMed ID: 27995877
[TBL] [Abstract][Full Text] [Related]
38. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Kastritis E; Dialoupi I; Gavriatopoulou M; Roussou M; Kanellias N; Fotiou D; Ntanasis-Stathopoulos I; Papadopoulou E; Ziogas DC; Stamatelopoulos K; Manios E; Ntalianis A; Eleutherakis-Papaiakovou E; Papanikolaou A; Migkou M; Papanota AM; Gakiopoulou H; Psimenou E; Tselegkidi MI; Tsitsilonis O; Kostopoulos I; Terpos E; Dimopoulos MA
Blood Adv; 2019 Oct; 3(20):3002-3009. PubMed ID: 31648323
[TBL] [Abstract][Full Text] [Related]
39. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
40. A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement.
Li T; Huang X; Wang Q; Zhao L; Ren G; Chen W; Zheng C; Zhou M; Jiang Q; Yin R; Liu Z
Br J Haematol; 2019 Nov; 187(4):459-469. PubMed ID: 31348519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]